Nothing Special   »   [go: up one dir, main page]

WO2020166709A1 - Dispositif de volatilisation de produit chimique - Google Patents

Dispositif de volatilisation de produit chimique Download PDF

Info

Publication number
WO2020166709A1
WO2020166709A1 PCT/JP2020/005855 JP2020005855W WO2020166709A1 WO 2020166709 A1 WO2020166709 A1 WO 2020166709A1 JP 2020005855 W JP2020005855 W JP 2020005855W WO 2020166709 A1 WO2020166709 A1 WO 2020166709A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
container
volatilization device
volatilizer
chemical
Prior art date
Application number
PCT/JP2020/005855
Other languages
English (en)
Japanese (ja)
Inventor
千佳 小倉
Original Assignee
アース製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アース製薬株式会社 filed Critical アース製薬株式会社
Priority to JP2020572344A priority Critical patent/JP7582870B2/ja
Publication of WO2020166709A1 publication Critical patent/WO2020166709A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01M—CATCHING, TRAPPING OR SCARING OF ANIMALS; APPARATUS FOR THE DESTRUCTION OF NOXIOUS ANIMALS OR NOXIOUS PLANTS
    • A01M1/00—Stationary means for catching or killing insects
    • A01M1/20—Poisoning, narcotising, or burning insects

Definitions

  • the present invention relates to a drug volatilization device including a drug volatilizer holding a drug that is volatile at room temperature, and a container having an opening for accommodating the drug volatilizer inside and exposing the drug volatilizer to the outside.
  • the conventional drug volatilization device described above uses the air (wind) flowing around the drug volatilization device to volatilize the drug, and depending on the direction (air direction) of the air flow, etc., the amount and volatilization range of the drug Can be different.
  • the container of the drug volatilization device has a simple flat structure
  • when air flows into the drug volatilization device from the side As compared with the case where air flows in from the front side, it has been revealed that the amount and range of vaporization of the drug are inferior.
  • the amount of volatilization and the range of volatilization of the drug are inferior, the effects of pest control and the like are naturally impaired. From the viewpoint of properly exerting the effect of the drug volatilization device, it is desired to suppress the variation in the amount of the drug volatilized due to the direction (wind direction) of the air flowing around the drug volatilization device.
  • One of the objects of the present invention is to provide a drug volatilization device that can suppress variations in the amount of drug volatilization and the like due to the direction (wind direction) of air flowing around the drug volatilization device.
  • the drug volatilization device comprises: A drug volatilizer holding a drug that is volatile at room temperature, and a container having an opening that accommodates the drug volatilizer inside and exposes the drug volatilizer to the outside,
  • the container is In a predetermined cross section along the thickness direction of the container, a plate-shaped structure configured such that a portion distant from the peripheral edge portion of the container has a protruding shape that protrudes in the thickness direction from the peripheral edge portion.
  • Have The drug volatilizer is It has a shape bent along the protruding shape.
  • the container is Both the surface on one side and the surface on the other side in the thickness direction are configured to have the protruding shape.
  • the container in the drug volatilization device according to the first aspect or the second aspect, is The protruding shape in the cross section is configured to be line-symmetrical with the central portion of the container sandwiched therebetween.
  • the drug in the drug volatilization device according to any one of the first to third aspects, contains at least one selected from the drug group consisting of profluthrin, enpentrin, transfluthrin and metofluthrin.
  • the cross-sectional shape has a specific protruding shape (that is, a portion separated from the peripheral portion of the container is
  • a container that has a shape that protrudes in the thickness direction from the peripheral portion By using a container that has a shape that protrudes in the thickness direction from the peripheral portion), it is clear that excellent pest control effects can be achieved regardless of the direction (wind direction) of the air flowing around the drug volatilization device.
  • the drug volatilization device of this configuration can suppress variations in the amount of volatilization of the drug and the like due to the direction (wind direction) of air flowing around the drug volatilization device.
  • both the one side surface and the other side surface in the thickness direction of the container have been described above. It was clarified that the variation in the amount of volatilization of the drug can be suppressed by having the projecting shape. Therefore, with this configuration, the effect of the drug volatilization device is properly exhibited.
  • the cross-sectional shape of the container is line-symmetrical with respect to the central portion of the container. It was clarified that variations in the amount of volatilization of the drug can be further suppressed as compared with the case without the drug. Therefore, with this configuration, the effect of the drug volatilization device is more appropriately exerted.
  • the present composition by using a pyrethroid drug having an excellent control effect against insects (that is, at least one selected from profluthrin, enpentrin, transfluthrin and metofluthrin), the present composition
  • the pest control can be properly performed using the chemical volatilization device.
  • a drug volatilization device capable of suppressing variations in the amount of drug volatilization and the like due to the direction (wind direction) of air flowing around the drug volatilization device.
  • FIG. 1 is an external view of a drug volatilization device according to an embodiment of the present invention.
  • FIG. 2 is an exploded perspective view of the drug volatilization device of FIG. 1.
  • 3A and 3B are cross-sectional views taken along the line AA of FIG.
  • FIG. 4(a) is a conceptual diagram showing the flow of air around the drug volatilization device when air flows into the drug volatilization device of FIG. 1 from the side
  • FIG. It is a conceptual diagram showing the flow of air in the periphery of a chemical volatilization device when air flows in from the front side with respect to 1 chemical volatilization device.
  • FIG. 5 is a schematic diagram showing a state of an evaluation test performed using the chemical volatilization apparatus of FIG. 1.
  • FIG. 1 is an external view of a drug volatilization device according to an embodiment of the present invention.
  • FIG. 2 is an exploded perspective view of the drug volatilization device of FIG. 1.
  • 3A and 3B are cross-
  • FIG. 6(a) is a view corresponding to FIGS. 3(a) and 3(b) of a drug volatilization device according to a first modification of the present invention
  • FIG. 6(b) is a view of the present invention. It is a figure corresponding to Drawing 3 (a) and Drawing 3 (b) about a medicine volatilization device concerning the 2nd modification.
  • FIG. 7(a) is a view corresponding to FIG. 3(a) and FIG. 3(b) of a drug volatilization device according to a third modified example of the present invention, and FIG. 7(b) is of the present invention. It is a figure corresponding to Drawing 3 (a) and Drawing 3 (b) about a medicine volatilization device concerning the 4th modification.
  • the chemical volatilization apparatus 10 according to the embodiment of the present invention will be described with reference to the drawings.
  • the longitudinal direction of the drug volatilization apparatus 10 is referred to as the “vertical direction”
  • one direction orthogonal to the “vertical direction” is referred to as the “width direction”
  • the “vertical direction” and “width direction” One direction orthogonal to is defined as "thickness direction”.
  • one side of the “thickness direction” in which the drug volatilization device 10 projects in a convex shape is referred to as a “front side”, and the other side is referred to as a “back side”.
  • the drug volatilization apparatus 10 has a vertically long rectangular shape that is long in the vertical direction in FIG.
  • this shape is merely an example, and the shape of the drug volatilization device 10 is not limited to the shape shown in FIG. 1.
  • the drug volatilization device 10 may have a horizontally long rectangular shape that is long in the width direction in FIG. 1, a square shape, or another polygonal shape. It may have a circular or elliptical shape.
  • the drug volatilization device 10 stores the drug volatilizer 20 holding the drug that is volatile at room temperature and the drug volatilizer 20. And a container 30 having a plate-like shape that defines the accommodation space S therein.
  • the chemical volatilization device 10 has a rectangular shape in which the height (the length in the vertical direction in FIG. 1) is longer than the width (the length in the width direction) as a whole, and the central portion in the width direction is on the front side. It has a curved shape so as to project.
  • the container 30 has a front housing 31, a back housing 32, and a string-shaped hanging portion 33 attached to the back housing 32.
  • the front housing 31 has a center in a cross section along the thickness direction of the container 30 that is separated from the peripheral edge portions 31 a on both sides in the width direction of the container 30.
  • the portion 31b has a protruding shape that protrudes more toward the front side in the thickness direction than the peripheral portion 31a.
  • the front housing 31 has a substantially flat flat region R1 in a predetermined range from the peripheral portion 31a toward the inner side in the width direction, and the front housing 31 has a flat region R1 in the range from the central portion 31b to the flat region R1.
  • Has a curved region R2 that is gently curved so as to be recessed inward in the width direction.
  • the maximum length A of the container 30 in the thickness direction is divided by the maximum length Z of the container 30 in the width direction.
  • the value (A/Z) is defined as “protrusion amount X”
  • the center position P of the projecting end of the central portion 31 b of the front housing 31 and the peripheral portion of the rear housing 32 Regarding the end positions Q and R in the width direction on the rear surface of 32a, a line segment that connects one of the end positions Q and R (Q in this example) to the central position P and a line segment that connects both the end positions Q and R.
  • the angle ⁇ formed by and is defined as “projection angle ⁇ ” the projection angle ⁇ is preferably 11 to 87 degrees, and more preferably 21 to 84 degrees.
  • a central portion 32b distant from the peripheral edge portions 32a on both sides in the width direction of the container 30 is larger than the peripheral edge portion 32a. It has a protruding shape that protrudes to the front side in the thickness direction.
  • the rear housing 32 has a flat region R1 and a curved region R2 similar to the front housing 31.
  • a storage space S having a shape corresponding to the above-described protruding shape is defined between the front housing 31 and the rear housing 32.
  • the chemical volatilization body 20 has a shape that is curved so as to follow the protruding shapes of the front housing 31 and the rear housing 32.
  • the front side casing 31 and the rear side casing 32 are sandwiched between the front side casing 31 and the rear side casing 32 while sandwiching the drug volatilizer 20.
  • the drug volatilizer 20 is housed in the housing space S by joining and in the state of being overlapped with each other in the thickness direction.
  • the chemical volatilization body 20 has such flexibility that it can be accommodated in the accommodation space S as described above (details will be described later).
  • a method using a locking member for joining the front housing 31 and the back housing 32
  • a method by heat fusion for joining the front housing 31 and the back housing 32
  • An example of a method of using the locking member is a method in which one of the front-side housing 31 and the back-side housing 32 is provided with a not-shown claw portion and the other is provided with a recess, and the claw portion is locked in the recess.
  • the front-side housing 31 and the back-side housing 32 may be configured to be detachable by using such a locking member, or may be configured to be non-detachable by thermal welding or adhesion.
  • the front housing 31 has a plurality of openings 31c for exposing the drug volatilization body 20 stored in the storage space S to the outside.
  • four openings 31c are arranged side by side in the vertical direction on one side in the width direction of the central portion 31b of the front housing 31, and on the other side in the width direction of the central portion 31b, The four openings 31c are arranged in the vertical direction.
  • Each of the openings 31c extends in the width direction while curving along the shape of the curving region R2 (see FIGS. 3A and 3B) of the front housing 31.
  • the front housing 31 may have an opening 31c in the central portion 31b.
  • each opening 32c extends in the width direction while curving along the shape of the curving region R2 (see FIGS. 3A and 3B) of the rear housing 32.
  • the rear housing 32 may have an opening 32c in the central portion 32b.
  • the number, arrangement, and shape of the openings 31c and the openings 32c are not particularly limited as long as the air around the medicine volatilization device 10 can contact the medicine volatilizer 20 through the openings 31c and the openings 32c.
  • the number, arrangement, and shape of the openings 31c and the openings 32c can be appropriately adjusted.
  • the front-side housing 31 and the back-side housing 32 are provided with the openings 31c and 32c having substantially the same number, arrangement, and shape.
  • 32 may be provided with openings 31c and 32c having different numbers, arrangements, and shapes.
  • the material forming the front housing 31 and the rear housing 32 is not particularly limited, and for example, resin, metal, glass, paper, wood, ceramics, or the like can be used.
  • the suspending unit 33 is used to suspend the drug volatilization device 10 at a predetermined place indoors or outdoors. For example, by suspending the chemical volatilization device 10 by using the suspending portion 33 around the entrance and exit of a building, which is a place where flying insects such as mosquitoes and flies invade, and openings such as windows, the insect pests can be controlled. .. Further, the chemical volatilization device 10 may be used for the purpose of, for example, aroma and deodorization in the toilet or room, and sterilization.
  • a net using a fiber material can be cited.
  • This net generally has a large number of vent holes and is excellent in the effect of volatilizing the drug.
  • the fiber material used for the net can be produced, for example, by knitting threads of short fibers or long fibers using a technique such as lace knitting or knitting.
  • the thread material include natural fibers such as pulp, cotton, wool, hemp and silk, polypropylene, polyethylene, polyamide, polyethylene terephthalate, polybutylene terephthalate, polysulfone, rayon, methacrylic acid resin and biodegradable resin (for example, Examples thereof include polyglycolic acid, polylactic acid, and poly( ⁇ -hydroxybutyric acid)).
  • the fiber material may contain additives such as an antifungal agent, a dye, an ultraviolet absorber and a fragrance.
  • the ratio of the total area of the vent holes to the total area of the net is preferably 5 to 80%, more preferably 10 to 50%.
  • the chemicals held by the chemical volatilizer 20 are chemicals that can volatilize at room temperature, and include various pest control agents (insecticides and repellents), fragrances, deodorants/deodorants, fungicides, fungicides, etc. It may be appropriately selected from various drugs according to the purpose and is not particularly limited. As the drug, only one kind may be used, or two or more kinds may be used.
  • Examples of the pest control agent include various insecticides such as organophosphorus, carbamate, and pyrethroids, repellents, and insect growth regulators.
  • organophosphorus insecticides include DDVP and diazinon
  • examples of carbamate insecticides include propoxur
  • examples of pyrethroid insecticides include phthalthrin, pralethrin, tefluthrin, transfluthrin, metfluthrin, dimefluthrin, and the like. Examples include mepafluthrin, profluthrin, enpentrin and terrarethrin.
  • profluthrin, enpentrin, transfluthrin, and metofluthrin are preferable because of their excellent insecticidal effect.
  • Other pest control agents include plant essential oils, terpenes, and their isomers and derivatives.
  • fragrance for example, lavender oil, musk, dragonfly, abies oil, citronella oil, eucalyptus oil, fennel oil, garlic oil, ginger oil, grapefruit oil, lemon oil, lemongrass oil, nutmeg oil, peppermint oil.
  • Essential oils such as orange oil, turpentine oil and sage oil, pinene, limonene, linalool, geraniol, citronellal, borneol, benzyl alcohol, anis alcohol, anethole, eugenol, aldehyde, citral, citronellal, vanillin, carvone, ketone, menthone, Examples thereof include acetophenone, coumarin, cineol, ethyl acetate, octyl acetate, linalyl acetate, butyl cyclohexyl acetate, butyl cycloheptyl acetate, isopropyl isobutyrate, allyl caproate, ethyl benzoate, methyl cinnamate and methyl salicylate.
  • Essential oils such as orange oil, turpentine oil and sage oil, pinene, limonene, linalool,
  • deodorant/deodorant examples include benzyl acetate, benzyl propionate, amylcinnamic aldehyde, anisic aldehyde, diphenyl oxide, methyl benzoate, ethyl benzoate, methyl phenylacetate, ethyl phenylacetate, neoline, safrole, citronella. Oil and lemongrass oil and the like can be mentioned.
  • bactericide examples include IPMP (isopropylmethylphenol), PCMX (p-chloro-m-xylenol), AIT (allyl isothiocyanate), hinokitiol, and stabilized chlorine dioxide.
  • IPMP isopropylmethylphenol
  • PCMX p-chloro-m-xylenol
  • AIT allyl isothiocyanate
  • hinokitiol and stabilized chlorine dioxide.
  • the drug may contain various additives as long as the effects of the present invention are not impaired.
  • the additive include a potency enhancer, a volatilization rate improver and a stabilizer.
  • the additive only one kind may be used, or two or more kinds may be used.
  • volatilization rate improver examples include phenethyl isothiocyanate.
  • stabilizer examples include 3,5-di-t-butyl-4-hydroxytoluene, 3-t-butyl-4-hydroxyanisole, mercaptobenzimidazole, dilauryl-thio-di-propionate and 2,2′- Methylene-bis-(6-t-butyl-4-methylphenol), 4,4'-methylene-bis-(2,6-di-t-butylphenol), 4,4'-thio-bis-(6- t-butyl-3-methylphenol), phenyl- ⁇ -naphthylamine, 2-t-butyl-4-methoxyphenol, stearyl- ⁇ -(3,5-di-t-butyl-4-hydroxyphenyl)propionate, ⁇ -Tocopherol, ascorbic acid, erythorbic acid and the like.
  • the method for holding the drug in the drug volatilizer 20 is not particularly limited.
  • a method of impregnating a drug, a method of kneading a drug into a net, or the like can be used.
  • the solvent may be removed by impregnating the net with the chemical and then drying.
  • the solvent for preparing the solution of the drug is not particularly limited, for example, water, naphthene, kerosene, hydrocarbons such as paraffin, glycerin, propylene glycol, dipropylene glycol, hexylene glycol, methanol, isopropanol, Alcohols such as 1-octanol and 1-dodecanol, ketones such as acetone and acetophenone, dihexyl ether, diethylene glycol diethyl ether, dipropylene glycol monomethyl ether, dipropylene glycol monobutyl ether and dipropylene glycol dimethyl ether, adipic acid Examples thereof include dioctyl, diethyl malonate, diethyl phthalate, and other esters, xylene, and silicone oil.
  • hydrocarbons such as paraffin, glycerin, propylene glycol, dipropylene glycol, hexylene glycol, methanol, iso
  • the amount of the drug held in the drug volatilizer 20 may be appropriately determined in consideration of the type of drug and the like so as to exert a desired effect (volatility or effective period). Further, the chemical volatilization body 20 may be configured as a replaceable cartridge type. When the drug volatilization apparatus 10 is used for a long period of time and all or almost all of the drug volatilizes and the effect of the drug disappears or decreases, the drug volatilizer 20 is replaced with a new one, thereby exhibiting the excellent effect again. be able to.
  • the airflow A flows into the drug volatilization device 10 from the side (the side facing the peripheral edge portion 31a)
  • a part of the airflow A is shown as the airflow A1.
  • the airflow contacts the drug volatilizer 20 through the opening 31c provided in the front housing 31 of the container 30, and the drug is appropriately volatilized on the front side of the drug volatilization device 10.
  • a part of the air flow A2 flowing out to the back side of the drug volatilization body 20 has an opening 32c of the back side housing 32, an opening of the drug volatilization body 20 and the front side housing 31 as shown in the air flow A3.
  • the portion 31c is again penetrated in the thickness direction, and flows out toward the width direction outer side (right side in the drawing) of the drug volatilization device 10.
  • the drug is appropriately volatilized outside the width direction of the drug volatilization device 10.
  • the other part of the air flow B penetrates the opening 31c of the front housing 31, the drug volatilizer 20, and the opening 32c of the rear housing 32 in the thickness direction. Then, it flows out toward the back side of the chemical volatilization device 10. As a result, the drug is properly volatilized on the back side of the drug volatilization device 10. Even when an air flow flows into the drug volatilizer 20 from the back side, the drug is volatilized along a path substantially similar to that shown in FIG.
  • the drug volatilization device 10 As described with reference to FIGS. 4A and 4B, by using the drug volatilization device 10, even when the airflow A flows into the drug volatilization device 10 from the side. Even when the air flow B flows into the drug volatilization device 10 from the front side, the drug is appropriately volatilized around the drug volatilization device 10. In other words, it is possible to suppress the variation in the amount and range of vaporization of the drug due to the direction of the air flow flowing into the drug volatilization device 10.
  • the drug volatilization apparatus 10 was configured using the container 30 and the drug volatilizer 20 having the shapes described below.
  • a drug in which 250 mg of liquid paraffin as a solvent and 500 mg of transfluthrin as a pest controlling component were mixed was dropped into the drug volatilizer 20 and impregnated therein.
  • the impregnated amount is 3.6 mg/cm 2 when converted per unit area of the chemical volatilizer 20.
  • the opening ratio of the opening 31c of the front housing 31 is 30%, and the opening ratio of the opening 32c of the rear housing 32 is 25%.
  • the drug volatilizer 20 has a rectangular shape shown in FIG. 2 as a whole.
  • the chemical volatilizer 20 has a height of 14 cm in the vertical direction of FIG. 2, a width of 10 cm in the width direction of FIG. 2, and a thickness of 0.9 mm in the thickness direction of FIG. It has a thin plate shape.
  • the chemical volatilizer 20 is made of polyester and has a net-like structure.
  • a drug volatilization apparatus 90 was configured using a container and a drug volatilizer having the shapes described below.
  • the drug volatilizer was impregnated with a drug in which 250 mg of liquid paraffin as a solvent and 500 mg of transfluthrin as a pest controlling component were mixed by using the same method as in the above-described example.
  • the amount of impregnation is 3.6 mg/cm 2 when converted per unit area of the drug volatilizer.
  • the container according to the comparative example has a flat shape that does not have a protruding shape like the container 30 according to the embodiment.
  • the container according to the comparative example has a thin plate-like rectangular parallelepiped shape having a height of 17 cm, a width of 11 cm, and a thickness of 1 cm.
  • this container has a front side housing and a back side housing similar to the container 30 according to the embodiment, and the opening ratio of the opening of the front side housing is 30%.
  • the aperture ratio of the part is 25%.
  • the drug volatilizer according to the comparative example has a flat shape corresponding to the container according to the comparative example described above. Specifically, the drug volatilizer according to the comparative example has a thin plate-like shape having a height of 14 cm, a width of 10 cm, and a thickness of 0.9 mm.
  • This chemical volatilizer is composed of polyester.
  • the chemical volatilization apparatus 10 As shown in FIG. 5, the chemical volatilization apparatus 10 according to the example is arranged at a height of 100 cm from the floor in the center of the room of the test room (8 tatami: length 3.6 m ⁇ width 3.6 m ⁇ height 2.4 m). Then, a cage containing adult Aedes albopictus (approximately 20 animals) as test insects was placed at a height of 75 cm from the floor at 5 locations (1st to 5th locations indicated by numbers 1 to 5 in the figure) along the wall of the test room. I placed it in The first location where the cage is arranged is on the side of the chemical volatilization device 10 (that is, on the side opposite to the side on which the air flow enters).
  • the second location is between the lateral side and the front side of the drug volatilization device 10.
  • the third location is on the front side of the drug volatilization device 10.
  • the fourth location is on the back side of the drug volatilization device 10.
  • the fifth location is between the back side and the side of the drug volatilization apparatus 10.
  • the chemical volatilization device 10 and each cage are arranged with an interval of about 1.5 m.
  • the values of KT50 of the example and the comparative example regarding the air flow and the cage position (first position) on the extension line of the chemical volatilization device 10 are shown.
  • the drug volatilization device 10 according to the example does not have an air flow and a cage position (from the second position to the second position) that is not on the extension line of the drug volatilization device 10. It was revealed that the knockdown effect was also stable at (5 locations), and the variation in the pest control effect in each cage was small. That is, it has been clarified that even when the air flow is introduced from the side of the drug volatilization device 10, the drug is diffused to all places around the drug volatilization device 10 and the pest control effect can be properly exerted.
  • the drug volatilization apparatus 10 can suppress variations in the amount of volatilization and the volatilization range of the drug caused by the direction of the air flow flowing into the drug volatilization device 10, as compared with the drug volatilization device 90 of the comparative example. It was
  • the present invention is not limited to the above-described embodiments, and various modifications can be adopted within the scope of the present invention.
  • the present invention is not limited to the above-described embodiments, and can be modified, improved, and the like as appropriate.
  • the material, shape, size, number, arrangement position, etc. of each constituent element in the above-described embodiment are arbitrary and are not limited as long as the present invention can be achieved.
  • the container 30 of the drug volatilizer 20 has a shape shown in FIGS. 1, 2, 3(a) and 3(b).
  • the shape of the container 30 may be such that the central portion 31b apart from the peripheral edge portion 31a of the container 30 in the cross section along the thickness direction of the container 30 has a protruding shape in which the central portion 31b protrudes in the thickness direction from the peripheral edge portion 31a.
  • the shapes are not limited to those shown in FIGS. 1, 2, 3A and 3B.
  • the container 30 may have a central portion 31b projecting more than the peripheral edge portion 31a and an arcuate projecting shape between the central portion 31b and the peripheral edge portion 31a as shown in FIG. 6A.
  • the central portion 31b as shown in FIG. 6(b) may protrude from the peripheral portion 31a, and the central portion 31b and the peripheral portion 31a may have a flat plate-like protruding shape.
  • FIGS. 6A and 6B the detailed internal structure of the drug volatilizer 20 and the like is omitted for convenience. The same applies to the sectional views shown in FIGS. 7A and 7B, which will be described later.
  • a plurality of (two in this example) portions 31d apart from the peripheral edge portion 31a are protruded in the thickness direction from the peripheral edge portion 31a, and these portions 31d are formed. It may have a protruding shape in which an arc is formed between the edge portion 31a and the peripheral portion 31a and an arc is formed between the portion 31d and the central portion 31b.
  • a plurality of (two in this example) portions 31d project in the thickness direction more than the peripheral edge portion 31a, and a portion between these portions 31d and the peripheral edge portion 31a is formed. It may have a projecting shape that is flat and the flat between the portion 31d and the central portion 31b.
  • [1] It has a drug volatilizer (20) holding a drug that is volatile at room temperature, and openings (31c, 32c) that house the drug volatilizer (20) inside and expose the drug volatilizer (20) to the outside.
  • a drug volatilization device (10) comprising a container (30), The container (30) is In a predetermined cross section along the thickness direction of the container (30), the parts (31b, 32b, 31d) apart from the peripheral parts (31a, 32a) of the container (30) are the peripheral parts (31a, 32a).
  • a plate-like structure configured to have a protruding shape that protrudes in the thickness direction
  • the drug volatilizer (20) is It has a curved shape along the protruding shape, Chemical volatilization device.
  • the container (30) is Both the surface on the one side and the surface on the other side in the thickness direction are configured to have the protruding shape, Chemical volatilization device.
  • the container (30) is The protruding shape in the cross section is configured to be line-symmetrical with respect to the central portion of the container (30). Chemical volatilization device.
  • the drug is At least one selected from the group of drugs consisting of profluthrin, enpentrin, transfluthrin and metofluthrin, Chemical volatilization device.
  • the drug volatilization device of the present invention can suppress variations in the amount of volatilization of the drug and the like due to the direction (wind direction) of the air flowing around the drug volatilization device.
  • the present invention having this effect can be used for controlling harmful insects such as mosquitoes.
  • Chemical Volatilizer 20 Chemical Volatilizer 30 Container 31 Front Side Housing 32 Back Side Housing 31a, 32a Peripheral Part 31b, 32b Central Part 31c, 32c Opening 33 Hanging Part

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Insects & Arthropods (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Catching Or Destruction (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Un dispositif de volatilisation de produit chimique (10) comprend : un corps de volatilisation de produit chimique (20) qui retient un produit chimique qui est volatil à température ambiante ; et un récipient (30) qui dispose d'ouvertures (31c, 32c). Le récipient (30) a une structure plate qui est conçue de telle sorte que, dans une section transversale prescrite le long de la direction de son épaisseur, des parties (31b, 32b, 31d) qui sont séparées des parties de bord circonférentiel (31a, 32a) ont une forme saillante qui fait saillie plus loin dans la direction de l'épaisseur que les parties de bord circonférentiel (31a, 32a). Le corps de volatilisation de produit chimique (20) a une forme qui est incurvée de façon à suivre la forme saillante.
PCT/JP2020/005855 2019-02-14 2020-02-14 Dispositif de volatilisation de produit chimique WO2020166709A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020572344A JP7582870B2 (ja) 2019-02-14 2020-02-14 薬剤揮散装置

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019-024600 2019-02-14
JP2019024600 2019-02-14

Publications (1)

Publication Number Publication Date
WO2020166709A1 true WO2020166709A1 (fr) 2020-08-20

Family

ID=72044060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/005855 WO2020166709A1 (fr) 2019-02-14 2020-02-14 Dispositif de volatilisation de produit chimique

Country Status (1)

Country Link
WO (1) WO2020166709A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7569075B2 (ja) 2021-01-21 2024-10-17 フマキラー株式会社 薬剤放散器

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340120B1 (en) * 2000-01-14 2002-01-22 David K. Seymour Scent dispensing device
JP2005333943A (ja) * 2004-05-31 2005-12-08 Toppan Printing Co Ltd 衣類用の防虫剤容器
JP5252659B2 (ja) * 2009-12-08 2013-07-31 フマキラー株式会社 虫除け用薬剤放散器
JP6182316B2 (ja) * 2013-01-11 2017-08-16 フマキラー株式会社 薬剤放散器
JP2018093778A (ja) * 2016-12-12 2018-06-21 アース製薬株式会社 薬剤揮散装置
JP2019170170A (ja) * 2018-03-27 2019-10-10 株式会社大阪製薬 害虫防除具

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340120B1 (en) * 2000-01-14 2002-01-22 David K. Seymour Scent dispensing device
JP2005333943A (ja) * 2004-05-31 2005-12-08 Toppan Printing Co Ltd 衣類用の防虫剤容器
JP5252659B2 (ja) * 2009-12-08 2013-07-31 フマキラー株式会社 虫除け用薬剤放散器
JP6182316B2 (ja) * 2013-01-11 2017-08-16 フマキラー株式会社 薬剤放散器
JP2018093778A (ja) * 2016-12-12 2018-06-21 アース製薬株式会社 薬剤揮散装置
JP2019170170A (ja) * 2018-03-27 2019-10-10 株式会社大阪製薬 害虫防除具

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7569075B2 (ja) 2021-01-21 2024-10-17 フマキラー株式会社 薬剤放散器

Also Published As

Publication number Publication date
JPWO2020166709A1 (ja) 2021-12-16

Similar Documents

Publication Publication Date Title
US7790000B2 (en) Volatilizer
JP5647003B2 (ja) 蒸散材
JP5275848B2 (ja) 薬剤揮散体および薬剤揮散体を用いた害虫の防虫方法
JP5137591B2 (ja) 薬剤揮散体
WO2020166709A1 (fr) Dispositif de volatilisation de produit chimique
JP5556790B2 (ja) ピレスロイド系化合物の光・紫外線劣化が防止された組成物及び光・紫外線劣化防止方法
JP5805521B2 (ja) ドアノブ用薬剤揮散体
JP2009131243A (ja) 害虫防除装置
JP5718143B2 (ja) 蒸散材
JP7582870B2 (ja) 薬剤揮散装置
JP2010090048A (ja) 薬剤揮散体
JP5385501B2 (ja) 蒸散材、吸血害虫の吸血前行動低下剤および蒸散方法
JP7477830B2 (ja) 薬剤揮散装置
JP2007230894A (ja) 害虫忌避方法
JP6904693B2 (ja) 薬剤揮散装置
JP5879033B2 (ja) エアカーテン装置
JP5948010B2 (ja) ゴキブリ侵入防止用薬剤揮散装置
JP7188980B2 (ja) トランスフルトリンの揮散促進方法、トランスフルトリン揮散促進剤および薬剤揮散組成物
JP7485583B2 (ja) 薬剤揮散装置、及び、薬剤揮散方法
JP2016042859A (ja) 揮発性物質収納容器
JP6348091B2 (ja) ゴキブリ侵入防止用薬剤揮散装置
JP2012140384A (ja) 網戸に固定して用いる薬剤揮散体及びこれを用いた飛翔害虫防除方法。
JP2024052192A (ja) 薬剤揮散装置
JP2019041581A (ja) 薬剤揮散容器及び薬剤揮散装置
JP5145576B2 (ja) 気流拡散装置

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20756395

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020572344

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20756395

Country of ref document: EP

Kind code of ref document: A1